RareStone Group logo

RareStone Group

To become the leading company in China rare disease market

25 employees · est. 2019 · China

VS
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals

Achieve better treatment processes and outcomes by combining global expertise and strength in endocrine therapies

42 employees · est. 2018 · China

VISEN Pharmaceuticals is the older company (2019 vs 2018).

Side-by-Side Comparison

RareStone Group VISEN Pharmaceuticals
Founded
2019 2018 older
Headquarters
China China
Employees
25 42
Industry
Pharmaceutical Biotechnology, Life Sciences, Pharmaceutical
Funding Stage
Series A Series B
Total Funding
$80.00M $190.00M
Funding Rounds
1 2
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Rare Diseases, Pharmaceuticals, Healthcare Services, China Market, Therapeutic Solutions, Service Platform, Rare Disease Community, Series A Financing, Investors, Neurology, Endocrinology, AI And Big Data Analytics, Patient-centered Care, Ecosystem Development Biopharmaceutical, Endocrine Therapies, Patient-centric Care, R&D, Pharmaceutical, Investment, Series B Financing, Innovation, Treatment Processes, Multinational, China Market, Ascendis Pharma A/S, VIVO Capital
Website
rarestonegroup.com visenpharma.com
RareStone Group logo

About RareStone Group

RareStone Group is on a mission to revolutionize the rare disease market in China. The company's subsidiaries, Citrine Medicine and Zircon Health, are pioneering a comprehensive ecosystem for rare diseases. Citrine Medicine focuses on delivering effective and affordable therapeutic solutions across...

VISEN Pharmaceuticals logo

About VISEN Pharmaceuticals

Visen Pharmaceuticals is an innovative biopharmaceutical company dedicated to providing innovative therapies and compassionate, patient-centric care for endocrine diseases. Their focus on endocrine diseases in adults and children, and rare endocrine diseases reflects their commitment to addressing d...

We will tell you when either one moves

BounceWatch watches RareStone Group and VISEN Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at RareStone Group and VISEN Pharmaceuticals — by email.

Frequently Asked Questions

RareStone Group — To become the leading company in China rare disease market . VISEN Pharmaceuticals — Achieve better treatment processes and outcomes by combining global expertise and strength in endocrine therapies. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
RareStone Group has raised $80.00M while VISEN Pharmaceuticals has raised $190.00M.
RareStone Group and VISEN Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare RareStone Group with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at RareStone Group on 12 Sep 2024, and VISEN Pharmaceuticals on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy